0 TSX News - January 10, 2024Aura Announces Q4 2023 Production Results, 7% above Q3 2023ROAD TOWN, British Virgin Islands, Jan. 10, 2024 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA, B3: AURA33 and OTCQX: […]Read More
0 Canadian Stock Exchange News - January 10, 2024Vortex Energy Commences Drill Trail Clearing Process at the Robinsons River Salt Project, Newfoundland & LabradorVANCOUVER, British Columbia, Jan. 10, 2024 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX | OTC: VTECF | FRA: AA3) […]Read More
0 NYSE Companies - January 10, 2024AIMイムノテック (AIM ImmunoTech)、膵臓がん治療を目的としたアストラゼネカ (AstraZeneca) のImfinzi® (デュルバルマブ) との併用によるAmpligen® (リンタトリモド) を評価する第Ib/II相試験の登録開始を発表オランダ、ロッテルダムのエラスムス医療センター (Erasmus Medical Center) で、間もなく最初の登録および最初の被験者への投与を予定 経営陣による同発表とその意義についての説明は動画を参照されたい。 フロリダ州オカラ発, Jan. 11, 2024 (GLOBE NEWSWIRE) — AIMイムノテック (AIM ImmunoTech Inc.) [...]Read More
0 NYSE Companies - January 10, 2024AIM ImmunoTech 宣布开展评估 Ampligen® (rintatolimod) 与 AstraZeneca 的 Imfinzi® (durvalumab) 联合用药治疗胰腺癌疗效的 1b/2 期研究的开放招募首次招募和首例受试者用药预计将很快将在荷兰罗特丹的 Erasmus Medical Center 进行 管理层在以下视频中对本公告及其意义进行了讨论,视频链接为:视频 奥卡拉,佛罗里达州, Jan. 11, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.(美国 NYSE:AIM)(简称“AIM”或“公司”)今日宣布,在 Erasmus [...]Read More
0 TSX News - January 10, 2024Middlefield Announces Intention to Convert International Clean Power Dividend Fund Into Infrastructure Dividend Split CorpTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Middlefield Limited (the “Manager”), the manager of International Clean Power Dividend Fund (“CLP”), […]Read More
0 TSX News - January 10, 2024Middlefield Announces Real Estate Fund MergerTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Middlefield is pleased to announce that Sustainable Real Estate Dividend Fund (“Real Estate […]Read More
0 NYSE Companies - January 10, 2024Prestige Consumer Healthcare Inc. to Release Fiscal 2024 Third Quarter Earnings ResultsTARRYTOWN, N.Y., Jan. 10, 2024 (GLOBE NEWSWIRE) — Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its […]Read More
0 TSX News - January 10, 2024Alamos Gold Achieves Increased 2023 Guidance with Record Annual Production and Provides Three-Year Production and Operating GuidanceTORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Alamos Gold Inc. (TSX:AGI; NYSE:AGI) (“Alamos” or the “Company”) today reported fourth quarter […]Read More
0 NYSE Companies - January 10, 2024Postal Realty Trust, Inc. Provides Fourth Quarter and Full Year 2023 UpdateAcquired 223 Properties for $78 Million in 2023 Full Year 2023 Weighted Average Capitalization Rate of 7.7% 96% of Debt […]Read More
0 NASDAQ Companies - January 10, 2024Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Jan. 10, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2024, […]Read More